Actively Recruiting
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
Led by Tianjin Medical University · Updated on 2026-01-30
500
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the potential usefulness of 11C/18F-MET/FET positron emission tomography/computed tomography (PET/CT) imaging for diagnosing primary and metastatic lesions in patients with various amino acid transporter system (AATS)-related diseases, including primary hyperparathyroidism and glioma. The study aims to measure how well this imaging method detects these lesions by analyzing uptake values and diagnostic accuracy. Each participant receives a single intravenous injection of the 11C/18F-MET/FET tracer, followed by PET/CT imaging within a specified time frame. This observational study involves patients undergoing the scan either for initial assessment or to detect recurrence of disease. The imaging uptake in lesions will be quantified using the maximum standardized uptake value (SUVmax). Participants will be evaluated with PET/CT scans, and the researchers will assess diagnostic measures such as sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. The primary outcome is the standardized uptake value measured within 30 days, along with diagnostic efficacy. The total study period extends up to the end date in 2033, with assessments occurring shortly after imaging.
CONDITIONS
Brief Title
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology reports
- Patients scheduled for AATS PET/CT scan
- Patients able to provide informed consent and assent according to ethical guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single intravenous injection of 11C/18F-MET/FET and undergo PET/CT imaging for initial assessment or recurrence detection of AATS-related diseases.
1 visit (in-person)
Duration - 30 days
Participants are monitored for diagnostic outcomes such as standardized uptake value and diagnostic efficacy for up to 30 days after imaging.
Follow-up assessments as scheduled
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China, 230000
Actively Recruiting
2
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
H
Haonan Yu, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here